GALAPAGOS NV

Lakefront Biotherapeutics announced the repurchase of 103,970 of its own shares between August 3 and August 7, 2026, as part of a program initiated on June 9, 2026. The total cost for these repurchases amounted to €2,409,901.40, with an average price of €23.18 per share. Following these transactions, the company holds 808,186 of its own ordinary shares as of August 7, 2026.

Lakefront Biotherapeutics (formerly Galapagos NV) announced its half-year 2026 financial results, reporting a net profit of €16.6 million, a significant turnaround from a net loss in the prior year, despite an 87% decrease in total net revenues to €18.6 million. The company completed the acquisition of Ouro Medicines with Gilead Sciences to advance gamgertamig, a potential first-in-class T-cell engager, which has received US FDA Fast Track and Orphan Drug Designation. Lakefront maintained its year-end 2026 cash and financial investments guidance of approximately €2 billion, including a newly announced €50 million share repurchase program. The company forecasts at least €1.6 billion in cash remaining for additional strategic transactions after funding gamgertamig to its first approval.

Lakefront Biotherapeutics announced it repurchased 97,497 of its own shares between July 27 and July 31, 2026. These repurchases, part of a program announced on June 9, 2026, totaled €2,386,239.93 at an average price of €24.48 per share. As of July 31, 2026, the company holds 704,216 of its own ordinary shares.

Lakefront Biotherapeutics announced the repurchase of 95,670 of its own shares between July 20 and July 24, 2026. This action was part of a previously announced repurchase program. The total cost for these shares amounted to €2,431,442.30, with an average price of €25.41 per share. Following these transactions, the company now holds 606,719 of its ordinary shares.

Lakefront Biotherapeutics NV announced the repurchase of 98,648 of its own shares between July 13, 2026, and July 17, 2026. This buyback was conducted as part of a program announced on June 9, 2026, through a discretionary mandate to an independent financial intermediary. The total value of the repurchased shares amounted to €2,564,633.73 at an average price of €26.00 per share. Following these transactions, Lakefront holds 511,049 of its own ordinary shares.

Lakefront Biotherapeutics announced the repurchase of 108,645 of its own shares between July 6 and July 10, 2026, as part of a previously announced program. The shares were acquired at an average price of €26.67, totaling €2,897,722.65. Following these transactions, Lakefront Biotherapeutics holds 412,401 of its own ordinary shares as of July 10, 2026.

Lakefront Biotherapeutics NV announced the repurchase of 104,022 of its own shares between June 29, 2026, and July 3, 2026, as part of a program initiated on June 9, 2026. The total value of these repurchases amounted to €2,730,010.70, with an average price of €26.24 per share. Following these transactions, the company holds 303,756 of its own ordinary shares as of market close on July 3, 2026.

Lakefront Biotherapeutics received a transparency notification from Madison Avenue Partners. The notification indicates that Madison Avenue Partners, jointly with its affiliates, crossed above the 5% voting rights threshold on June 15, 2026. As of June 24, 2026, Madison Avenue Partners holds 3,498,892 voting rights, representing 5.31% of Lakefront's total outstanding shares.

Lakefront Biotherapeutics NV announced the initiation of a share repurchase program, allowing the company to repurchase ordinary shares for an aggregate amount of up to 50 million euros. Repurchases may be made no later than December 31, 2026. This program stems from an opportunity gained through a transaction with Gilead announced in March 2026, which permitted repurchases of up to $150 million. The primary objective of the program is to deliver shareholder value, with all purchased shares to be held as treasury shares.

Lakefront Biotherapeutics announced the appointment of Eric Hedrick, MD, as its new Chief Medical Officer. This leadership expansion supports the company's strategic transformation following its recent acquisition of Ouro Medicines' operational assets. Dr. Hedrick brings 25 years of experience in developing effective and commercially successful therapies in the pharmaceutical and biotechnology industry.